Breast Disorders: Benign Fibrocystic Changes, Benign Neoplasms, and Malignant Breast Cancer

Benign/Fibrocystic Breast Changes

  • Pathophysiology
    • Presence of palpable breast masses; a group of lesions in the breast.
    • Size of lesions fluctuates with the menstrual cycle.
  • Etiology
    • Hormonal imbalance during reproductive years.
  • Clinical manifestations
    • Tenderness or pain in one or both breasts prior to the menstrual cycle.
    • Palpable cysts: firm, regular shape, mobile.
  • Diagnosis
    • Breast examination.
    • Mammogram.
    • Ultrasound with biopsy or needle aspiration when indicated.
  • Treatment and management
    • Oral contraceptives to control symptoms.
    • NSAIDs for pain relief.
    • Avoidance of certain foods containing methylxanthines (tea, coffee, cola, chocolate).
    • Low-fat, high-carbohydrate diet shown to decrease breast swelling and tenderness.
  • Important caveat regarding cancer risk
    • Note: It was previously thought that all women with fibrocystic breast changes had an increased risk of breast cancer; recent research has disproved this.

Benign Specific Neoplasms of the Breast

  • Pathophysiology/Pathogenesis
    • Encapsulated masses that do not invade surrounding tissue or metastasize.
    • May occur at any time from childhood to old age.
  • Etiology
    • Abnormal cells.
  • Clinical manifestations
    • Freely movable/palpable masses.
    • Masses are sharply delineated from surrounding breast tissue.
  • Diagnosis
    • Breast examination.
    • Mammogram.
    • Ultrasound with biopsy.
  • Examples
    • Fibroadenomas, adenomas, papillomas.

Malignant (Breast Cancer)

  • Overview and epidemiology
    • Carcinoma of the breast remains the most common form of cancer in women aged 25–75 years.
    • In the United States, it is the second leading cause of cancer mortality in women.
  • Etiology
    • Abnormal/cancerous cells invade breast tissue.
Risk factors and possible causes (well-supported by research)
  • Hormonal influences
    • Women with more than 40 years of menstrual activity have approximately 2 imes the breast cancer risk compared with women with fewer than 30 years of menstrual activity.
    • Postmenopausal hormone replacement therapies (HRT) are implicated as a risk-modifying factor.
  • Reproductive factors
    • Early age at first birth reduces risk; first birth at age 35 or older increases risk.
    • Low parity (fewer viable children) increases risk; high parity has a protective effect.
  • Dietary factors
    • High-fat diet associated with increased risk.
  • Family history and genetics
    • BRCA1 and BRCA2 gene mutations markedly increase risk for breast and ovarian cancers.
    • Individuals at high risk may consider prophylactic options:
    • Prophylactic salpingo-oophorectomy to reduce risk.
    • Bilateral mastectomy for those at very high risk.
    • Chemoprevention with selective estrogen receptor modulators (SERMs); examples include tamoxifen or raloxifene.
    • SERMs can reduce risk but may cause thromboembolic events and increase endometrial cancer risk.
Age-related incidence and other risk factors
  • Age: Incidence begins to rise after age 25–30 and continues to increase with advancing age.
  • Radiation exposure.
  • Personal history of cancer.
Clinical manifestations (presentation)
  • Palpable lump (mass)
  • Pain is not always present; lump may be:
    • Painless
    • Hard and immovable
    • Associated signs in advanced disease: nipple retraction, skin dimpling, and bloody discharge.
Diagnosis and screening
  • Diagnostic approach
    • Self breast examination (SBE) routinely encouraged.
    • Mammography: recommended yearly starting at age 40.
    • Ultrasound with biopsy when indicated.
    • Magnetic resonance imaging (MRI) as an adjunct in certain scenarios.
  • Note on imaging findings and follow-up
    • Imaging guides biopsy decisions and helps differentiate benign from malignant lesions.

Summary of Key Points for Exam

  • Fibrocystic changes are common and related to hormonal fluctuations; they are not inherently cancerous, though symptoms warrant evaluation.
  • Benign neoplasms are encapsulated and do not metastasize; common examples include fibroadenomas, adenomas, and papillomas.
  • Breast cancer risk is influenced by hormonal exposure, reproductive history, diet, and genetics (BRCA1/2).
  • High-risk individuals may pursue risk-reduction strategies (salpingo-oophorectomy, bilateral mastectomy, SERMs).
  • Screening and diagnosis emphasize SBE, yearly mammography from age 40, and ultrasound with biopsy when indicated; MRI can be used selectively.
  • Clinical signs of advanced breast cancer include hard, immovable masses, nipple retraction, skin changes, and possibly pathologic discharge.
  • Statistically, breast cancer is the most common cancer in women ages 25–75 and the second leading cause of cancer mortality in women in the US; risk factors can modify likelihood but do not determine fate for any single individual.

Key Formulas and Numerical References

  • Risk associated with extended menstrual activity: if R{ ext{>40}} represents risk for women with >40 years of menstrual activity and R{ ext{≤30}} for those with ≤30 years, then approximately
    R<em>ext>40≈2 R</em>ext≤30.R<em>{ ext{>40}} \approx 2 \, R</em>{ ext{≤30}}.
  • Hormonal influence note: postmenopausal hormone replacement therapy is a factor in risk modification (no single numeric multiplier provided in the transcript).
  • SERMs: chemoprevention reduces risk but carries risks of thromboembolism and endometrial cancer.